Clinical Trial Update: Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: A Randomized Controlled Trial [Phase 2, Phase 3]

View source ↗

Summary

A randomized study is evaluating postoperative radiotherapy with Nimotuzumab, with or without Benmelstobart, for intermediate-risk head and neck squamous cell c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Benmelstobart
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING